Incidence and Risk of Glucocorticoid‐Associated Adverse Effects in Patients With Rheumatoid Arthritis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: Using the UK Clinical Practice Research Datalink, we examined the incidence of glucocorticoid (GC)‐related serious adverse events (SAE s) in rheumatoid arthritis (RA) and non‐RA patients and quantified the risk of SAE s in patients with RA. Methods: We matched incident patients with RA to an age‐ and sex‐matched, non‐RA comparison group of equal size. In a cohort analysis, we estimated incidence rates (IR s) and IR ratios (IRR s) for GC‐related AE s (i.e., diabetes mellitus [DM], osteoporosis, fractures, glaucoma, hypertension, gastrointestinal [GI] perforation or bleeding, thrombotic stroke or myocardial infarction [MI], or death), stratified by GC use. We conducted a series of nested case–control analyses among patients with RA, evaluating the effects of increasing cumulative and average daily GC dose. Cases of each outcome were matched to controls for age, sex, and general practice. We calculated adjusted odds ratios (OR s) with 95% confidence intervals (95% CI s) for each outcome. Results: Patients with RA had a higher incidence for all investigated SAE s except glaucoma, compared to non‐RA patients. IRR s were greater in those patients prescribed a GC than in those without. In patients with RA, GC s were associated with an elevated risk of DM (adjusted OR 1.33 [95% CI 1.14–1.56]), osteoporosis (adjusted OR 1.41 [95% CI 1.25–1.59]), thrombotic stroke or MI (adjusted OR 1.28 [95% CI 1.07–1.52]), serious infection (adjusted OR 1.28 [95% CI 1.11–1.48]), and death (adjusted OR 1.33 [95% CI 1.19–1.48]). There was a trend of increasing risk with increasing cumulative and average daily GC dose for all outcomes other than glaucoma, hypertension, and GI perforations or bleeding (P < 0.05). Conclusion: Patients with RA had an increased incidence of GC‐related AE s. Increasing cumulative and average daily GC doses were found to be associated with an increasing risk of developing an AE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 9×
“The Clinical Practice Research Datalink (CPRD) is a well- validated database that contains anonymized health care information on more than 10 million patients in the UK.”
BackgroundInfluentialThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604
del Rincón, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M., & Escalante, A. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38210 · Cited by 264
Movahedi, M., Costello, R., Lunt, M., Pye, S. R., Sergeant, J. C., & Dixon, W. G. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0167-1 · Cited by 58
Cited by
George, M. D., Baker, J. F., Winthrop, K., Hsu, J. Y., Wu, Q., Chen, L., Xie, F., Yun, H., & Curtis, J. R. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1594 · Cited by 198
“We did not evaluate the risks for other adverse outcomes (for example, fracture, cataracts, diabetes, and cardiovascular events), which have been associated with low-dose glucocorticoids in some studies (18).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Burmester, G. R., Buttgereit, F., Bernasconi, C., Álvaro-Gracia, J. M., Castro, N., Dougados, M., Gabay, C., van Laar, J. M., Nebesky, J. M., Pethoe-Schramm, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30636-x · Cited by 128
Glucocorticoid use is associated with an increased risk of hypertension
Costello, R. E., Yimer, B. B., Roads, P., Jani, M., & Dixon, W. G. (2021) · Rheumatology · doi:10.1093/rheumatology/keaa209 · Cited by 64
Metadata
- Authors
- Wilson, J. C., Sarsour, K., Gale, S., Pethö‐Schramm, A., Jick, S. S., & Meier, C. R.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2019-03-28
- Volume
- 71
- Issue
- 4
- Pages
- 498-511
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W2805740714
- Cited by
- 111
- References
- 6
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence and Risk of Glucocorticoid‐Associated Adverse Effects in Patients With Rheumatoid Arthritis. https://app.cochat.ai/papers/10.1002/acr.23611
- The paper
- Wilson, J. C., Sarsour, K., Gale, S., Pethö‐Schramm, A., Jick, S. S., & Meier, C. R. (2019). Incidence and Risk of Glucocorticoid‐Associated Adverse Effects in Patients With Rheumatoid Arthritis. Arthritis Care & Research. https://doi.org/10.1002/acr.23611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.